Monofree (Dexamethasone Phosphate)

Dexamethasone phosphate binds to glucocorticoid receptors in ocular tissues, altering gene transcription that suppresses pro‑inflammatory cytokines and mediators. This reduces leukocyte infiltration and stabilises cell membranes, leading to decreased inflammation and immune response within the eye.

The specific dosage and frequency of Monofree are determined by the prescribing ophthalmologist based on the severity of the condition, the patient’s response, and clinical guidelines. The prescriber will provide individualized instructions for each case.

Safety data for dexamethasone phosphate in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use during pregnancy or while nursing should only occur if the potential benefit outweighs any possible risk, and under medical supervision.

To place an order, submit an enquiry on the Monofree product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with other ocular corticosteroids such as prednisolone acetate, dexamethasone phosphate offers a potent anti‑inflammatory effect with a relatively short ocular half‑life, allowing rapid reduction of inflammation. Choice of agent depends on physician preference, formulation availability and patient‑specific factors.

Store Monofree at room temperature, preferably below 25 °C, in its original packaging. Protect the container from direct sunlight, moisture and extreme temperature fluctuations to maintain product stability and potency.

Monofree is applied as an ophthalmic solution directly onto the affected eye(s) using the supplied dropper. The prescriber will indicate the number of drops per dose and the dosing interval, typically ranging from one to several times daily, depending on the condition being treated.

The most serious adverse effects include elevated intra‑ocular pressure that can lead to glaucoma, cataract formation, and rare hypersensitivity reactions such as severe eye irritation or allergic conjunctivitis. Patients should be monitored regularly for these complications.

Monofree should be avoided in patients with known hypersensitivity to dexamethasone phosphate or any component of the formulation, active ocular infections of viral, fungal or bacterial origin, and in individuals where systemic corticosteroid therapy is contraindicated without specialist advice.